Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy

Journal of Medical Virology

Volumn 85, Issue 5, 2013, Pages 755-759

  Ucciferri, Claudio ^a,b   Falasca, Katia ^b   Vignale, Francesca ^b   Di Nicola, Marta ^b   Pizzigallo, Eligio ^b   Vecchiet, Jacopo ^b  

^a UNIVERSITY OF MOLISE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Cholesterol; Dyslipidemia; Fosamprenavir; Lopinavir; Triglycerides

Indexed keywords

CYSTATIN C; DARUNAVIR PLUS RITONAVIR; FOSAMPRENAVIR PLUS RITONAVIR; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG SUBSTITUTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL PARAMETERS; KIDNEY FUNCTION; LIPID METABOLISM; LIVER FUNCTION; MALE; MICROALBUMINURIA; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTI-HIV AGENTS; BLOOD CHEMICAL ANALYSIS; CARBAMATES; CD4 LYMPHOCYTE COUNT; DYSLIPIDEMIAS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; KIDNEY FUNCTION TESTS; LIVER FUNCTION TESTS; MALE; METABOLOME; MIDDLE AGED; ORGANOPHOSPHATES; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; RITONAVIR; SULFONAMIDES;

EID: 84875677476     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23543     Document Type: Article

References (16)

1. Arpegard J, Ostergren J, de Faire U, Hansson LO, Svensson P. 2008. Cystatin C-A marker of peripheral atherosclerotic disease? Atherosclerosis 199:397-401.
2. Audelin AM, Lebech AM, Petersen AB, Jorgensen LB. 2008. Follow-up of a multi-drug resistant HIV-1 infected patient successfully treated with darunavir and etravirine. J Med Virol 80:1319-1321.
3. Baekken M, Os I, Sandvik L, Oektedalen O. 2008. Microalbuminuria associated with indicators of inflammatory activity in an HIV-positive population. Nephrol Dial Transplant 23:3130-3137.
4. Calza L, Manfredi R, Chiodo F. 2004. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 53:10-14.
5. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, Wohrmann A, Katlama C, Wilkin T, Haubrich R, Cohen C, Farthing C, Jayaweera D, Markowitz M, Ruane P, Spinosa-Guzman S, Lefebvre E. 2007. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 369:1169-1178.
6. De Meyer SM, Spinosa-Guzman S, Vangeneugden TJ, de Bethune MP, Miralles GD. 2008. Efficacy of once-daily darunavir/ritonavir 800/100mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir. J Acquir Immune Defic Syndr 49:179-182.
7. Eron J, Jr., Yeni P, Gathe J, Jr., Estrada V, DeJesus E, Staszewski S, Lackey P, Katlama C, Young B, Yau L, Sutherland-Phillips D, Wannamaker P, Vavro C, Patel L, Yeo J, Shaefer M. 2006. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial. Lancet 368:476-482.
8. Falasca K, Manigrasso MR, Racciatti D, Zingariello P, Dalessandro M, Ucciferri C, Mancino P, Marinopiccoli M, Petrarca C, Conti P, Pizzigallo E, Guagnano MT, Vecchiet J. 2006. Associations between hypertriglyceridemia and serum ghrelin, adiponectin, and IL-18 levels in HIV-infected patients. Ann Clin Lab Sci 36:59-66.
9. Falasca K, Ucciferri C, Manzoli L, Mancino P, Pizzigallo E, Conti P, Vecchiet J. 2007. Metabolic syndrome and cardiovascular risk in HIV-infected patients with lipodystrophy. Int J Immunopathol Pharmacol 20:519-527.
10. Falasca K, Ucciferri C, Mancino P, Di Iorio A, Vignale F, Pizzigallo E, Vecchiet J. 2010. Cystatin C, adipokines and cardiovascular risk in HIV infected patients. Curr HIV Res 8:405-410.
11. Hill A, Sawyer W, Gazzard B. 2009. Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin Trials 10:1-12.
12. Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortes C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM. 2003. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 349:1036-1046.
13. Neuhaus J, Jacobs DR, Jr., Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH, Pett SL, Ristola M, Ross MJ, Shlipak MG, Tracy R, Neaton JD. 2010. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 201:1788-1795.
14. Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, Fourie J, De Meyer S, De Pauw M, Lefebvre E, Vangeneugden T, Spinosa-Guzman S. 2008. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 22:1389-1397.
15. Rubio R, Serrano O, Carmena J, Asensi V, Echevarria S, Flores J, Ribera E, Zarraga M, Ocampo A, de la Fuente B, Sepulveda MA, Marino AI, Minguez C, Vicent R, Carton JA, Moyano B, Esteban H, Mahillo B, Serrano L, Gonzalez-Garcia J. 2010. Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions. HIV Med 11:545-553.
16. Vecchiet J, Ucciferri C, Falasca K, Mancino P, Di Iorio A, De Caterina R. 2011. Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients. Antivir Ther 16:639-645.